NHS won’t get cutting-edge drugs unless it pays more, says AstraZeneca boss

Pascal Soriot says cost-effectiveness thresholds for new medicines have not changed for two decadesBusiness live – latest updatesThe boss of AstraZeneca has said that unless the UK ramps up spending on new drugs, it could be on a trajectory to only being able to afford cheap, generic medicines rather than cutting-edge treatments.Pascal Soriot made the remarks amid an acrimonious standoff between the pharmaceutical industry and the government over drug pricing, which has been blamed for drugmakers pausing or ditching nearly £2bn of investments in the UK this year. Continue reading...